Company profile: Bluebird Bio
1.1 - Company Overview
Company description
- Provider of gene therapies for severe genetic and rare diseases, developing gene addition treatments that modify patient cells to address underlying genetic causes using lentiviral vectors. Products include LentiGlobin for sickle cell disease, Lenti-D for cerebral adrenoleukodystrophy, and Zynteglo for beta-thalassemia.
Products and services
- Lenti-D for Cerebral Adrenoleukodystrophy: Clinical-stage therapy delivering a functional gene to cells to treat cerebral adrenoleukodystrophy and halt disease progression
- LentiGlobin for Sickle Cell Disease: Gene-addition therapy delivering a functional copy of the gene to cells to address sickle cell disease and correct its genetic basis
- Zynteglo for Beta-Thalassemia: Cell-modifying gene therapy enabling patients to produce functional hemoglobin, reducing or eliminating the need for blood transfusions by altering their cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bluebird Bio
Synlogic
HQ: United States
Website
- Description: Provider of synthetic biotic medicines designed to perform metabolic functions to treat diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlogic company profile →
PhyNexus
HQ: United States
Website
- Description: Provider of chromatography-enabled pipette tip columns for protein and plasmid purification, delivering high-throughput sample processing for life science researchers in drug discovery, screening, structural studies, and other workflows requiring very pure, highly concentrated products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhyNexus company profile →
Syngenta
HQ: Switzerland
Website
- Description: Provider of agricultural technologies and solutions that improve yields, crop resilience, and resource conservation. Offers crop protection from sowing to harvest; seeds and traits for grains, oilseeds, vegetables, fruits, and flowers; TYMIRIUM technology against nematodes and soil-borne pathogens; PERGADO Ultra fungicide for cocoa; and Shoots by Syngenta, a collaborative platform advancing sustainable agriculture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Syngenta company profile →
Antiva Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics targeting diseases caused by HPV infection, including ABI-2280, a topical prodrug designed to treat high-grade cervical intraepithelial neoplasias (HSIL, CIN 2,3) and high-risk HPV infections by blocking HPV replication and inducing apoptosis in infected cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Antiva Biosciences company profile →
Tango Therapeutics
HQ: United States
Website
- Description: Provider of next-generation cancer therapies leveraging synthetic lethality, including TNG908 and TNG462, PRMT5 inhibitors for MTAP-deleted cancers; TNG260, a CoREST inhibitor aimed at reversing immune evasion in STK11-mutant cancers; and TNG348, a USP1 inhibitor for BRCA1/2-mutant and other HRD+ cancers, all in Phase 1/2 trials. Also provides a CRISPR-based functional genomics platform to identify synthetic lethal targets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tango Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bluebird Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bluebird Bio
2.2 - Growth funds investing in similar companies to Bluebird Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bluebird Bio
4.2 - Public trading comparable groups for Bluebird Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →